Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
$7.38
-3.7%
$5.48
$3.50
$12.40
$473.08M1.542.53 million shs697,682 shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$9.25
-2.7%
$11.98
$9.23
$27.38
$120.69M0.26172,804 shs174,068 shs
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
$18.61
-2.0%
$17.56
$13.30
$24.99
$458.72M1.135,328 shs439 shs
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
$5.52
+0.7%
$5.83
$2.41
$7.37
$426.72M2.531.23 million shs1.28 million shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
-3.66%-0.40%+49.39%+39.51%+45.56%
Lifevantage Corporation stock logo
LFVN
Lifevantage
-2.73%-4.93%-23.62%-29.17%-20.80%
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
-0.80%+1.27%+13.90%+3.63%-9.16%
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
+0.73%-10.53%+0.36%0.00%-16.24%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
$7.38
-3.7%
$5.48
$3.50
$12.40
$473.08M1.542.53 million shs697,682 shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$9.25
-2.7%
$11.98
$9.23
$27.38
$120.69M0.26172,804 shs174,068 shs
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
$18.61
-2.0%
$17.56
$13.30
$24.99
$458.72M1.135,328 shs439 shs
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
$5.52
+0.7%
$5.83
$2.41
$7.37
$426.72M2.531.23 million shs1.28 million shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
-3.66%-0.40%+49.39%+39.51%+45.56%
Lifevantage Corporation stock logo
LFVN
Lifevantage
-2.73%-4.93%-23.62%-29.17%-20.80%
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
-0.80%+1.27%+13.90%+3.63%-9.16%
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
+0.73%-10.53%+0.36%0.00%-16.24%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
2.25
Hold$15.33107.77% Upside
Lifevantage Corporation stock logo
LFVN
Lifevantage
2.67
Moderate Buy$30.50229.73% Upside
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
1.00
SellN/AN/A
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
2.92
Moderate Buy$15.00171.74% Upside

Current Analyst Ratings Breakdown

Latest LFVN, GLUE, PRTC, and SLDB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/27/2025
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
9/27/2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C+)
9/27/2025
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
9/27/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
8/14/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$15.00
8/14/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$15.00 ➝ $13.00
8/13/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$17.00 ➝ $14.00
7/21/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetOverweight$16.00
(Data available from 10/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
$75.62M6.03N/AN/A$3.63 per share2.03
Lifevantage Corporation stock logo
LFVN
Lifevantage
$228.53M0.51$1.07 per share8.65$2.75 per share3.36
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
$4.83M93.10$2.34 per share7.96$17.04 per share1.09
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
$8.09M53.13N/AN/A$3.43 per share1.61
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
-$72.70M$0.3620.50N/AN/A13.58%9.95%6.42%11/6/2025 (Estimated)
Lifevantage Corporation stock logo
LFVN
Lifevantage
$9.81M$0.7412.50N/A4.29%33.75%15.26%11/4/2025 (Estimated)
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
$27.78MN/A0.00N/AN/AN/AN/AN/AN/A
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
-$124.70M-$2.80N/AN/AN/AN/A-69.70%-56.74%11/5/2025 (Estimated)

Latest LFVN, GLUE, PRTC, and SLDB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2025Q3 2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
-$0.42N/AN/AN/AN/AN/A
11/4/2025Q1 2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.17N/AN/AN/A$54.74 millionN/A
9/4/2025Q4 2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.17$0.17N/A$0.15$57.93 million$55.11 million
8/12/2025Q2 2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
-$0.51-$0.42+$0.09-$0.42N/AN/A
8/7/2025Q2 2025
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
-$0.31-$0.15+$0.16-$0.15$7.23 million$23.19 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
N/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.181.95%N/A24.32%3 Years
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
N/AN/AN/AN/AN/A
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
N/AN/AN/AN/AN/A

Latest LFVN, GLUE, PRTC, and SLDB Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/26/2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
quarterly$0.04501.57%9/8/20259/8/20259/16/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
N/A
7.16
7.16
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.87
1.11
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
N/A
8.49
N/A
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
N/A
9.34
9.34

Institutional Ownership

CompanyInstitutional Ownership
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
79.96%
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
0.04%
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
81.46%

Insider Ownership

CompanyInsider Ownership
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
6.50%
Lifevantage Corporation stock logo
LFVN
Lifevantage
21.95%
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
5.30%
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
13.63%
CompanyEmployeesShares OutstandingFree FloatOptionable
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
9061.76 million57.75 millionOptionable
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.69 million9.91 millionOptionable
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
10024.17 million22.89 millionNot Optionable
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
10077.87 million67.26 millionOptionable

Recent News About These Companies

Solid Bio Green on Fast Track Nod
SLDB - Solid Biosciences Inc Executives - Morningstar

New MarketBeat Followers Over Time

Media Sentiment Over Time

Monte Rosa Therapeutics stock logo

Monte Rosa Therapeutics NASDAQ:GLUE

$7.38 -0.28 (-3.66%)
Closing price 10/7/2025 04:00 PM Eastern
Extended Trading
$7.30 -0.08 (-1.08%)
As of 04:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$9.25 -0.26 (-2.73%)
Closing price 10/7/2025 04:00 PM Eastern
Extended Trading
$9.26 +0.01 (+0.05%)
As of 10/7/2025 04:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

PureTech Health stock logo

PureTech Health NASDAQ:PRTC

$18.60 -0.38 (-1.98%)
Closing price 10/7/2025 03:42 PM Eastern
Extended Trading
$18.60 0.00 (0.00%)
As of 10/7/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Solid Biosciences stock logo

Solid Biosciences NASDAQ:SLDB

$5.52 +0.04 (+0.73%)
Closing price 10/7/2025 04:00 PM Eastern
Extended Trading
$5.50 -0.02 (-0.36%)
As of 10/7/2025 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.